On the recordJuly 27, 2022
The FDA needs to provide regulatory pathways for products containing CBD. The FDA needs to act now.
Said by
Ryan F. Quarles
Source
congress.govThe FDA needs to provide regulatory pathways for products containing CBD. The FDA needs to act now.
Quarles emphasizes the urgency for FDA guidance on CBD products to stimulate investment.
Share
More from Ryan F. Quarles
The Federal Reserve, along with the other U.S. banking agencies, has made substantial progress in building stronger regulatory and supervisory programs since the global financial crisis.
If Congress does choose to provide a guarantee for mortgages, I would urge that the guarantee be explicit and transparent, done in a manner that protects taxpayers, and apply to securities not institutions.
Similarly, that has always been a high priority of the Federal Reserve, and where we have the enforcement authority to act, we will do that.